Ask AI
SDM in ET PV

CME

Empowering the Patient Voice: Shared Decision-making Strategies in ET and PV

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: March 31, 2026

Expiration: September 30, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Tefferi A, Gangat N, Loscocco GG, et al. Essential thrombocythemia: a review. JAMA. 2025;333:701-714.
  2. Harrison CN, Barbui T, Bose P, et al. Polycythaemia vera. Nat Rev Dis Primers. 2025;11:26.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myeloproliferative neoplasms. v1.2026. nccn.org. Accessed March 24, 2026.
  4. Josfeld L, Keinki C, Pammer C, et al. Cancer patients' perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol. 2021;147:1725-1732.
  5. Gravel K, Légaré F, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals' perceptions. Implement Sci. 2006;1:16.
  6. Légaré F, Ratté S, Gravel K, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions. Patient Educ Couns. 2008;73:526-535.
  7. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
  8. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
  9. Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166-179.
  10. Biagioli V, Inzoli A, Barone A, et al. The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis. Eur J Oncol Nurs. 2026;80:103047.
  11. Loh KP, Tsang M, LeBlanc TW, et al. Decisional involvement and information preferences of patients with hematologic malignancies. Blood Adv. 2020;4:5492-5500.
  12. Mayo SJ, Panesar P, Edwards B, Howell D. Information needs across time after a hematological cancer diagnosis: A qualitative study of patient and clinician perspectives. Patient Educ Couns. 2023;117:107970.
  13. Hawley ST, Morris AM. Cultural challenges to engaging patients in shared decision making. Patient Educ Couns. 2017;100:18-24.
  14. Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2011;22:761-772.
  15. Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared decision making in the care of patients with cancer. Am Soc Clin Oncol Educ Book. 2023;43:e389516.
  16. Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2017;123:449-458.
  17. Megeed A, Magas H, Accursi M, et al. The impact of a pharmacist-led oral anticancer clinic on medication adherence and laboratory monitoring. J Oncol Pharm Pract. 2023;29:1921-1927.
  18. Guan T, O'Donnell A, Varikkodan S, et al. "We are caring for the whole person": a qualitative study of social work's role in palliative cancer care. Palliat Support Care. 2026;24:e36.
  19. Oprea N, Ardito V, Ciani O. Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review. BMC Med Inform Decis Mak. 2023;23:164.
  20. Melas M, Subbiah S, Saadat S, et al. The community oncology and academic medical center alliance in the age of precision medicine: cancer genetics and genomics considerations. J Clin Med. 2020;9:2125.